Key regions: Australia, Germany, United Kingdom, United States, France
The Caribbean region has a growing demand for immunosuppressants due to the increasing prevalence of autoimmune diseases and organ transplantations.
Customer preferences: Patients in the Caribbean region prefer immunosuppressants that have fewer side effects and are cost-effective. They also tend to prefer medications that are easily accessible and have a longer shelf life.
Trends in the market: The Caribbean region is witnessing an increase in the use of biologics and biosimilars in the treatment of autoimmune diseases. Biologics such as monoclonal antibodies and fusion proteins have shown promising results in treating autoimmune diseases such as rheumatoid arthritis and psoriasis. Biosimilars, on the other hand, are gaining popularity due to their lower cost compared to biologics. The use of biosimilars is expected to increase in the coming years due to the patent expiration of several biologics.
Local special circumstances: The Caribbean region has a high prevalence of autoimmune diseases such as lupus, rheumatoid arthritis, and multiple sclerosis. This is due to a combination of genetic and environmental factors. The region also has a high incidence of kidney disease, which has led to an increase in the number of organ transplantations. The demand for immunosuppressants is expected to increase in the coming years due to the rising incidence of these diseases.
Underlying macroeconomic factors: The Caribbean region has a growing healthcare sector, which is expected to drive the demand for immunosuppressants. The region has also witnessed an increase in medical tourism, which has led to an increase in the number of organ transplantations. The availability of generic drugs and biosimilars is expected to drive down the cost of immunosuppressants, making them more affordable for patients. However, the region also faces challenges such as inadequate healthcare infrastructure and a shortage of healthcare professionals, which could hinder the growth of the immunosuppressants market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
